menu ☰
menu ˟

VIDEO: Ibalizumab continues to suppress MDR HIV after 48 weeks

13 Oct 2017
SAN DIEGO — In this video, Brinda Emu, MD, assistant professor of medicine at Yale University, reviews 48-week data of a phase 3 trial evaluating the safety and efficacy of ibalizumab in patients with multidrug-resistant HIV.Ibalizumab is a long-ac...

Click here to view the full article which appeared in

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.